News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...

One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential causes, biomarkers, and the significance of viral rebound. A virologist ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two injections per year to one against HIV. "It is a hopeful step and the study data are ...

As scientists gathered at the Conference for Retroviruses and Opportunistic Infections, or CROI, for meetings that run through Wednesday, they face an uncertain future. It was evident in who was ...

The Conference on Retroviruses and Opportunistic Infections 2025 (CROI) featured multiple sessions that focused on breaking research and treatments.

Ensitrelvir reduced transmission of SARS-CoV-2 by 67% when given to uninfected household contacts of a person with COVID-19 ...

Spotlight reports on this and some of the other exciting research on long-acting anti-HIV medicines presented at the ...

Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. "This study brought us a step forward in better understanding mpox disease ...

taking ensitrelvir within 72 hours of symptoms is effective at preventing infection and generally well tolerated, according ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, baseline suppressive therapies among adults with HIV.

Previous research has suggested an increased risk for neuropsychiatric symptoms in people living with HIV who are being ...

Injections of semaglutide were associated with significant improvement in cognitive function in people living with HIV (PWH), ...